Abstract
Spontaneous autoantibody responses against tumor-associated antigens have been detected in all types of cancer analyzed so far. Recent studies have shown that cancer-associated autoantibodies can be found in the serum of patients even several years before the clinical diagnosis. Furthermore, they may at least partially reflect the antigenic profile of cancer and the balance of immune cell subsets in the tumor microenvironment. Therefore, cancer associatedautoantibodies represent attractive biomarkers for the development of non-invasive serological tests for the diagnosis or early detection of cancer, prognosis of survival and prediction of the clinical benefit of immunotherapy. Still, the frequency of responses against each particular antigen is generally low and the autoantibody repertoire is highly heterogeneous and overlapping with that elicited by viral infections and autoimmune disorders, hence precluding the clinical use of single autoantibody biomarkers. This can, however, be overcome by analyzing the autoantibody responses to multiple antigens simultaneously. In this review, we discuss the diagnostic relevance of the recently identified cancer-associated autoantibody signatures and the challenges in the development of clinically applicable biomarker assays. In addition, the putative functional role and the significance of IgG subclasses in the anti-tumor immune response and their prognostic value are discussed.
Keywords: Autoantibodies, B cells, biomarkers, early detection of cancer, proteomics, tumor antigens.
Current Cancer Therapy Reviews
Title:Cancer-associated Autoantibodies as Biomarkers for Early Detection and Prognosis is Cancer: An Update
Volume: 9 Issue: 4
Author(s): Irena Meistere, Zane Kalnina, Karina Silina and Aija Line
Affiliation:
Keywords: Autoantibodies, B cells, biomarkers, early detection of cancer, proteomics, tumor antigens.
Abstract: Spontaneous autoantibody responses against tumor-associated antigens have been detected in all types of cancer analyzed so far. Recent studies have shown that cancer-associated autoantibodies can be found in the serum of patients even several years before the clinical diagnosis. Furthermore, they may at least partially reflect the antigenic profile of cancer and the balance of immune cell subsets in the tumor microenvironment. Therefore, cancer associatedautoantibodies represent attractive biomarkers for the development of non-invasive serological tests for the diagnosis or early detection of cancer, prognosis of survival and prediction of the clinical benefit of immunotherapy. Still, the frequency of responses against each particular antigen is generally low and the autoantibody repertoire is highly heterogeneous and overlapping with that elicited by viral infections and autoimmune disorders, hence precluding the clinical use of single autoantibody biomarkers. This can, however, be overcome by analyzing the autoantibody responses to multiple antigens simultaneously. In this review, we discuss the diagnostic relevance of the recently identified cancer-associated autoantibody signatures and the challenges in the development of clinically applicable biomarker assays. In addition, the putative functional role and the significance of IgG subclasses in the anti-tumor immune response and their prognostic value are discussed.
Export Options
About this article
Cite this article as:
Meistere Irena, Kalnina Zane, Silina Karina and Line Aija, Cancer-associated Autoantibodies as Biomarkers for Early Detection and Prognosis is Cancer: An Update, Current Cancer Therapy Reviews 2013; 9 (4) . https://dx.doi.org/10.2174/157339470904140418093612
DOI https://dx.doi.org/10.2174/157339470904140418093612 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Semi-dynamic Control of FCM Initialization for Automatic Extraction of Inflamed Appendix from Ultrasonography
Current Medical Imaging Withdrawal Notice: The Recent Advancement in the Field of Super Paramagnetic Iron Oxide Nanoparticles (SPIONs) for Aiming Breast Cancer
Current Drug Metabolism Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design Morphological Based Medical Image Processing on Cervical Cytology Cancer Images Using Connected Component Techniques
Current Medical Imaging Connexins as Precocious Markers and Molecular Targets for Chemical and Pharmacological Agents in Carcinogenesis
Current Medicinal Chemistry TNF-Related Apoptosis-Inducing Ligand (TRAIL) as a Pro-Apoptotic Signal Transducer with Cancer Therapeutic Potential
Current Pharmaceutical Design Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Roles of miRNA in the Initiation and Development of Colorectal Carcinoma
Current Pharmaceutical Design The HOX Gene Network as a Potential Target for Cancer Therapy
Current Cancer Therapy Reviews Genetically Modified Cellular Vaccines for Therapy of Human Papilloma Virus Type 16 (HPV 16)-Associated Tumours
Current Cancer Drug Targets Bombacaceae Between the Ethnomedical Uses and Pharmacological Evidences: A Review
The Natural Products Journal Design and Endpoints of Clinical and Translational Trials in Advanced Colorectal Cancer. A Proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD)
Reviews on Recent Clinical Trials Preparation of Cationic Lipid-coated Ultrasound Contrast Agents and Noninvasive Gene Transfection Via Ultrasound-targeted Microbubble Destruction
Current Pharmaceutical Design Editorial (Thematic Issue: Nanosystems: An Innovative Tools for Medicinal Chemistry)
Current Topics in Medicinal Chemistry Non Polymeric Nanoparticles for Photodynamic Therapy Applications: Recent Developments
Current Medicinal Chemistry Methodological Aspects and Applications of In Vivo Imaging of Apoptosis in Oncology: An Illustrative Review
Current Medical Imaging Modulation of Long Non-coding RNAs by Different Classes of Secondary Metabolites from Plants: A Mini-review on Antitumor Effects
Mini-Reviews in Medicinal Chemistry Secretory Leukocyte Protease Inhibitor: More than Just A Protease Inhibitor
Current Immunology Reviews (Discontinued) Functional Interplay between RNA-Binding Protein HuR and microRNAs
Current Protein & Peptide Science Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy
Current Topics in Medicinal Chemistry